Stable Gastric Pentadecapeptide BPC 157 in Trials for Inflammatory Bowel Disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and Distended Stomach, and Vascular Response

This review article explores the therapeutic potential of BPC 157, a stable gastric pentadecapeptide, in treating gastrointestinal disorders, particularly inflammatory bowel disease (IBD). Clinical trials (PL-10, PLD-116, PL 14736) have demonstrated its safety profile. BPC 157 exhibits cytoprotective and adaptive cytoprotective activities, promoting healing in various gastrointestinal lesions. In animal